Eli Lilly and Company’s (LLY) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Eli Lilly and Company (NYSE:LLYFree Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $885.00 price target on the stock.

A number of other research analysts also recently commented on LLY. JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an overweight rating in a research report on Wednesday, May 1st. Erste Group Bank upgraded shares of Eli Lilly and Company from a hold rating to a buy rating in a research note on Wednesday, April 3rd. Truist Financial raised their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a buy rating in a research note on Wednesday, May 1st. Morgan Stanley raised their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an overweight rating in a research note on Friday, February 16th. Finally, Bank of America raised their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a buy rating in a research note on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $787.53.

Check Out Our Latest Stock Analysis on Eli Lilly and Company

Eli Lilly and Company Stock Performance

Shares of LLY opened at $882.21 on Tuesday. The firm has a 50-day moving average of $784.08 and a 200-day moving average of $715.56. Eli Lilly and Company has a one year low of $434.34 and a one year high of $885.06. The company has a market cap of $838.46 billion, a PE ratio of 129.93, a price-to-earnings-growth ratio of 1.89 and a beta of 0.36. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter last year, the firm posted $1.62 EPS. The company’s quarterly revenue was up 26.0% on a year-over-year basis. As a group, equities analysts forecast that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 75,510 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $860.78, for a total value of $64,997,497.80. Following the transaction, the insider now directly owns 97,793,810 shares of the company’s stock, valued at approximately $84,178,955,771.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 75,510 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $860.78, for a total value of $64,997,497.80. Following the transaction, the insider now directly owns 97,793,810 shares of the company’s stock, valued at approximately $84,178,955,771.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the transaction, the executive vice president now directly owns 25,428 shares in the company, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold a total of 552,804 shares of company stock valued at $462,119,714 in the last ninety days. 0.13% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently made changes to their positions in LLY. Norges Bank bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $5,992,890,000. International Assets Investment Management LLC grew its holdings in shares of Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the last quarter. Swedbank AB bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at approximately $932,797,000. Sapient Capital LLC bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $682,139,000. Finally, Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after acquiring an additional 1,133,810 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.